Enhanced IL-1 and IL-6 expression has been observed in KRAS-mutant tumours [34], which leads to upregulation of IDO-1 in TILs via NF-kB and STAT3 signalling (Fig. 2) [90]. The gene discussed is KRAS; the disease is neoplasm.